Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Università Vita-Salute San Raffaele | OTHER |
Not provided
Not provided
Not provided
Not provided
Termination of cardiopulmonary bypass is a critical step in any cardiac surgical procedure and requires a thorough planning. Debate about rationale of calcium administration during weaning of cardiopulmonary bypass has been conducted for several decades; however, a consensus has not been yet reached.
Perioperative hypocalcemia can develop because of haemodilution or calcium binding from heparin, albumin and citrate. Perioperative hypocalcemia is often complicated by development of arrhythmias, especially QT interval prolongation. Furthermore, low content of calcium can lead to vascular tone disorders, violation of neuromuscular transmission, altered hemostasis and heart failure, resistant to inotropic agents, especially in patients with concomitant cardiomyopathy.
On the other hand, hypercalcaemia is a dangerous complication in cardiac surgery. Among the fatal, but rather rare complications, there are acute pancreatitis and the phenomenon of the "stone heart", which is essentially a reperfusion injury of the myocardium caused by rapid calcium overload. Hypercalcaemia can also trigger rhythm disturbances, hypertension, increase systemic vascular resistance, reduce diastolic compliance and impair relaxation of the myocardium due to excessive calcium intake into the cardiomyocytes, cause coronary vasospasm and aggravate ischaemic myocardial damage, impair arterial graft blood flow during aortocoronary and mammary coronary bypass surgery.
To date, there is a lack of data indicating clinical efficacy of calcium administration before separation from CPB. Therefore, we designed this randomized controlled trial to test the hypothesis whether calcium administration at termination of CPB will reduce the need for inotropic support at the end of surgery.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Calcium chloride | Experimental | Participants randomly assigned to the experimental group will receive 15 mg/kg of calcium chloride (bolus) intravenously during separation from cardiopulmonary bypass |
|
| 0,9% Sodium Chloride | Placebo Comparator | Participants randomly assigned to the placebo group will receive equivalent amount of placebo intravenously during separation from cardiopulmonary bypass |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Calcium Chloride | Drug | Calcium Chloride |
| |
| 0.9% Sodium Chloride |
| Measure | Description | Time Frame |
|---|---|---|
| Inotropic support | Number of patients requiring inotropic support before transfer to intensive care unit | Intraoperatively |
| Measure | Description | Time Frame |
|---|---|---|
| Duration of inotropic support after surgery | Duration of infusion of any vasoinotropic agent at any dose | 30 days after surgery |
| Vasoactive-inotropic score | Vasoactive-inotropic score will be measured on the morning of postoperative day 1. The inotropic score will be calculated using the following formula: Dobutamine dose (in mcg/kg/min) + Dopamine dose (in mcg/kg/min) + Enoximone dose (in mcg/kg/min) + [Epinephrine dose (in mcg/kg/min) x 100] + [Norepinephrine dose (in mcg/kg/min) x 100]. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Vladimir Lomivorotov | Meshalkin Research Institute of Pathology of Circulation | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Sh. Mohammed Bin Khalifa Bin Salman Al-Khalifa Cardiac Center | Manama | Bahrain | ||||
| Federal Center for Cardiovascular Surgery |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D002122 | Calcium Chloride |
| D012965 | Sodium Chloride |
| ID | Term |
|---|---|
| D017610 | Calcium Compounds |
| D007287 | Inorganic Chemicals |
| D002712 | Chlorides |
| D006851 | Hydrochloric Acid |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
0.9% Sodium Chloride |
|
| Postoperative day 1 |
| Plasma Ca2+ concentration before and after drug administration | Intraoperatively |
| Time spent in theatre after cardiopulmonary bypass | Intraoperatively |
| Duration of ventilation | Up to 30 day after randomization |
| Duration of intensive care unit stay | Up to 30 day after randomization |
| Myocardial infarction | Number of patients who develop myocardial infarction | Up to 30 day after randomization |
| Atrial fibrillation | Number of patients who develop postoperative atrial fibrillation | Up to 30 day after randomization |
| Type 1 and type 2 neurological complications | Number of patients who develop type 1 and type 2 develop myocardial infarction | Up to 30 day after randomization |
| Postoperative blood loss | Postoperative blood (ml/kg) loss will be measured on the morning of postoperative day 1 | Postoperative day 1 |
| Need for blood transfusion after surgery | Number of patients who will need transfuion of any blood products (red cells, fresh frozen plasma, cryoprecipitate) | Up to 30 day after randomization |
| Intraoperative myocardial ischemia | The presence of intraoperative myocardial ischemia will be defined during continuous intraoperative ECG monitoring after calcium chloride or placebo administration | Intraoperatively |
| Myocardial ischaemia on ECG after arrival to ICU | Number of patients who develop myocardial ischemia | Postoperative day 1 |
| Concentration of alpha-amylase after surgery | Postoperative day 1 |
| Internal mammary artery vascular resistance (if available) | Will be defined by intraoperative graft flow measurements | Intraoperatively |
| Astrakhan |
| Russia |
| Federal Center for Cardiovascular Surgery | Chelyabinsk | Russia |
| District clinical hospital | Khanty-Mansiysk | Russia |
| B.V. Petrovsky Russian Scientific Surgery Center | Moscow | Russia |
| M. Vladimirsky Moscow Regional Research Cinical Institute (MONIKI) | Moscow | Russia |
| Meshalkin Research Institute of Pathology of Circulation | Novosibirsk | 630055 | Russia |
| Federal Center for Cardiovascular Surgery | Penza | Russia |
| St Petersburg University Multifunctional Clinical Centre | Saint Petersburg | Russia |
| Tomsk National Research Medical Center | Tomsk | Russia |
| King Abdullah Medical City | Mecca | Saudi Arabia |
| D017606 |
| Chlorine Compounds |
| D017670 | Sodium Compounds |